Acebutolol
| Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
|---|---|---|---|
| Beta Blockers | Acebutolol | 100-150 mg Q12-24H | Administer Post HD session |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 336 | 30-40 | 3-4 (parent), 8-13 (active) | 7 | 26 | 1.2 | 42.6 | N/A |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB01193
- Roux A, Aubert P, Guedon J, Flouvat B. Pharmacokinetics of acebutolol in patients with all grades of renal failure. European journal of clinical pharmacology. 1980;17(5):339-48.